Citius Pharmaceuticals Inc (CTXR.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|71||2016||Executive Chairman of the Board, Secretary|
|69||2016||President, Chief Executive Officer, Director|
|2017||Chief Financial Officer, Principal Financial Officer|
- BRIEF-Citius Announces Enrollment Of First Patient In Mino-Lok Late Stage Trial
- BRIEF-Citius Announces $6 Mln Registered Direct Offering Priced At-The-Market
- BRIEF-Citius Pharmaceuticals Says On Nov 27, Board Appointed Jaime Bartushak As CFO And Principal Financial Officer Of Co
- BRIEF-Citius Pharmaceuticals files for mixed shelf offering of up to $50 mln - SEC filing
- BRIEF-Citius pharmaceuticals receives "fast track" designation by FDA for mino-lok™ investigational trial